GlassScriptPhysician profile
Mohammed S Antwi
NPI 1356442321
$2,473.35
in general payments reported to CMS, 2019-2025
26 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $652 · 2023: $340 · 2024: $549 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.20 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $588.58 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $310.81 | 2022-2025 | |
| Dexcom, INC. | $220.50 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $201.45 | 2021-2025 | Veozah |
| Lilly USA, LLC | $144.47 | 2022-2025 | Jardiance, Emgality, Kisunla |
| Novo Nordisk INC | $142.56 | 2021-2024 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.22 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.31 | 2021-2023 | Xifaxan |
| Pfizer INC. | $71.19 | 2021-2024 | |
| Inspire Medical Systems, INC. | $70.89 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $61.28 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $52.32 | 2021-2024 | Airsupra |
| Xeris Pharmaceuticals, INC. | $46.90 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $46.51 | 2022 | |
| Exact Sciences Corporation | $44.20 | 2024-2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $35.32 | 2022 | |
| Amgen INC. | $27.61 | 2021 | |
| Genentech USA, INC. | $25.23 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.62 | 2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $20.27 | 2024 | Rexulti |
| Amarin Pharma, INC. | $19.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.59 | 2022 | |
| Cranial Technologies, INC | $17.34 | 2025 | Doc Band |
| Cipher Pharmaceuticals US LLC | $15.80 | 2025 | Natroba, Spinosad |
| Takeda Pharmaceuticals U.S.A., INC. | $14.56 | 2021 | |
| Merck Sharp & Dohme LLC | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Antwi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.